Bioxytran’s ProLectin-M Posts Rapid Viral Clearance in Completed Phase 2 Trial
Bioxytran has reported positive results from a completed Phase 2 trial of its investigational antiviral candidate, ProLectin-M, pointing to what it describes as rapid and sustained viral clearance in people with laboratory-confirmed acute viral infection.
In the company’s topline summary, viral load was completely eliminated in all treated patients by day seven, with outcomes reported as superior to placebo.
The trial design: randomised, double-blind, placebo-controlled – and built around seven days
The study was structured as a randomised, double-blind, placebo-controlled, dose-optimisation trial.
It enrolled 38 participants, and Bioxytran said every subject completed the full seven-day treatment period – an important operational detail in a small study where dropouts can skew interpretation.
Participants received one of three oral ProLectin-M dose levels or a matching placebo.
How viral shedding was measured, and what “clearance” meant in this study
To track viral shedding, investigators used RT-PCR testing of nasopharyngeal swabs taken at predefined timepoints.
In practical terms, “clearance” was defined as viral RNA becoming non-detectable (below the established PCR thresholds) – a clear, laboratory-anchored endpoint that avoids subjective symptom scoring and focuses the question on viral presence itself.
The topline result: 100% of treated subjects cleared by day seven, with no rebounds reported
Following database lock and unblinding, Bioxytran reported that 100% of treated subjects achieved complete elimination of viral load by day seven, compared with placebo.
The company also said there were no viral rebounds observed during a 14-day post-treatment follow-up window – a detail it emphasised because rebounds can be a concern when viral suppression is temporary rather than sustained.
A closer look at the timing: day three, day five, day seven
Bioxytran’s public summary also included a simple timeline across the study cohort: one participant showed non-detection by day three, 16 by day five, and by day seven, viral RNA was reported as non-detectable across all 38 participants.
The company presented this as supportive evidence that clearance happened earlier than expected in a meaningful proportion of cases. (The announcement did not provide a full arm-by-arm breakdown of clearance timing beyond these topline statements.)
Dose optimisation: the trial narrows in on four tablets per day
Beyond the headline clearance result, this Phase 2 study had a practical purpose: dose selection.
Bioxytran said the latest trial refined its dosing choice to four tablets per day and tested whether rapid viral clearance could be reproduced using the same core virologic assessment approach.
In development terms, that’s the bridge between “interesting signal” and “repeatable regimen” – the kind of detail that determines whether a programme can realistically move into larger late-stage trials.
“Real-world” framing from the company’s Chief Medical Officer
Bioxytran’s Chief Medical Officer said the seven-day treatment window was designed to mirror real-world treatment of acute viral disease, with the goal of showing a statistically meaningful reduction in viral load by day seven.
In the company’s telling, the standout was speed: clearance occurred more rapidly than anticipated, with notable non-detection already appearing by day three and complete clearance by day seven in treated subjects.
Why Bioxytran says ProLectin-M is different: targeting entry, not replication
In most antiviral narratives, the battleground is replication inside the infected cell. Bioxytran is positioning ProLectin-M as a different kind of play: a galectin antagonist designed to interfere with viral entry at the cell surface – an extracellular strategy intended to block the virus before it gets established inside cells.
The company argues this mechanism is what supports ProLectin-M’s “broad-range” antiviral potential, because it aims at a step common to infection rather than a single virus-specific replication pathway.
What happens next: from Phase 2 signal to late-stage proof
Bioxytran says it plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M in additional viral indications consistent with a broad-spectrum profile.
As ever with Phase 2 announcements, the next question is scale: whether the same clearance dynamics hold up in larger, more diverse populations, with fuller public reporting of arm-level kinetics, safety, and clinical outcomes beyond laboratory measures.
Conclusion: a Phase 2 result that puts speed and durability centre stage
Bioxytran’s completed Phase 2, randomised, double-blind, placebo-controlled, dose-optimisation study of oral ProLectin-M has delivered the kind of headline numbers companies hope for: reported complete elimination of viral load in all treated subjects by day seven, no viral rebounds during a 14-day follow-up, and signs of earlier non-detection emerging as soon as day three.
With dose selection refined to four tablets per day and a mechanism aimed at blocking viral entry at the cell surface, the company is now positioning ProLectin-M as a broad-range antiviral candidate – and setting up the next, decisive step: demonstrating that this rapid viral clearance signal can be replicated at late-stage scale.
News Credits: Bioxytran reports rapid viral clearance in phase 2 trial
Things you may also like: